Compare Eli Lilly And Co (LLY) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs WD 40 Company — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while WD 40 Company trades at $202.23 (market cap $2.73B). The key difference: Eli Lilly And Co is far larger — about 381× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (2%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and WD 40 Company for 22 Days on average.
| LLY | WDFC | |
|---|---|---|
Market Cap | $1.04T | $2.73B |
Volume | 3,064,878 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $264.91 |
52-Week Low | $799.57 | $187.52 |
Typical Hold Time | 93 Days | 22 Days |
Enterprise Value | $1.09T | $2.79B |
Dividend Yield | 0.59% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
